AXSMAxsome Therapeutics
About Axsome Therapeutics
Axsome Therapeutics (NASDAQ:AXSM) is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) conditions. Their operations span the entire drug development process, from discovery through clinical trials, with a mission to improve the lives of patients suffering from disorders and diseases affecting the brain and the nervous system. Projects in their pipeline include treatments for major depressive disorder, Alzheimer's disease agitation, and chronic pain, among others. The objective of Axsome is to bring innovative and effective therapeutic solutions to market, addressing unmet medical needs within the realm of CNS disorders, thereby enhancing patient care and outcomes.
What is AXSM known for?
Snapshot
Public US
Ownership
2012
Year founded
516
Employees
New York, United States
Head office
1 of 2
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
New York City, US
Produtos e/ou serviços de Axsome Therapeutics
- Sunosi - for the treatment of excessive daytime sleepiness in narcolepsy or obstructive sleep apnea.
- AXS-05 - for Major Depressive Disorder and treatment-resistant depression.
- AXS-07 - for the acute treatment of migraine.
- AXS-12 - for the treatment of narcolepsy.
- AXS-14 - for the management of fibromyalgia.
- AXS-09 - for cognitive disorders including Alzheimer's disease.
equipe executiva do Axsome Therapeutics
- Dr. Herriot Tabuteau M.D.Founder, Chairman, CEO & President
- Mr. Nick Pizzie CPA, M.B.A.Chief Financial Officer
- Mr. Mark L. Jacobson M.A.Chief Operating Officer
- Mr. Hunter Murdock Esq.General Counsel & Secretary
- Mr. Ari MaizelChief Commercial Officer
- Darren OplandDirector of Corporate Communications